AIM ImmunoTech Inc. (AIM)
USD 0.2
(-6.89%)
USD 0.2
(-6.89%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 9.14 Million USD | 352.82% |
| 2022 | 2.02 Million USD | 146.34% |
| 2021 | 820 Thousand USD | -75.08% |
| 2020 | 3.29 Million USD | -55.01% |
| 2019 | 7.31 Million USD | -15.67% |
| 2018 | 8.67 Million USD | 57.54% |
| 2017 | 5.5 Million USD | 63.08% |
| 2016 | 3.37 Million USD | 38.72% |
| 2015 | 2.43 Million USD | -45.15% |
| 2014 | 4.43 Million USD | 72.67% |
| 2013 | 2.56 Million USD | -80.24% |
| 2012 | 12.99 Million USD | 134.3% |
| 2011 | 5.54 Million USD | -3.23% |
| 2010 | 5.73 Million USD | 119.24% |
| 2009 | 2.61 Million USD | 56.87% |
| 2008 | 1.66 Million USD | -23.78% |
| 2007 | 2.18 Million USD | -67.26% |
| 2006 | 6.68 Million USD | 38.16% |
| 2005 | 4.83 Million USD | -5.03% |
| 2004 | 5.09 Million USD | 22.5% |
| 2003 | 4.15 Million USD | 183.88% |
| 2002 | 1.46 Million USD | 15.09% |
| 2001 | 1.27 Million USD | -14.92% |
| 2000 | 1.49 Million USD | -0.33% |
| 1999 | 1.5 Million USD | 36.36% |
| 1998 | 1.1 Million USD | 37.5% |
| 1997 | 800 Thousand USD | -27.27% |
| 1996 | 1.1 Million USD | -86.75% |
| 1995 | 8.3 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.36 Million USD | 23.73% |
| 2024 Q2 | 9.61 Million USD | -15.4% |
| 2023 Q3 | 5.25 Million USD | 51.03% |
| 2023 FY | 9.18 Million USD | 354.64% |
| 2023 Q4 | 9.18 Million USD | 74.63% |
| 2023 Q2 | 3.48 Million USD | 40.8% |
| 2023 Q1 | 2.47 Million USD | 22.43% |
| 2022 Q1 | 854 Thousand USD | 4.15% |
| 2022 FY | 2.02 Million USD | 146.34% |
| 2022 Q4 | 2.02 Million USD | -43.73% |
| 2022 Q3 | 3.59 Million USD | 70.63% |
| 2022 Q2 | 2.1 Million USD | 146.37% |
| 2021 Q3 | 1.03 Million USD | -13.19% |
| 2021 FY | 820 Thousand USD | -75.08% |
| 2021 Q4 | 820 Thousand USD | -20.62% |
| 2021 Q1 | 3.12 Million USD | -5.11% |
| 2021 Q2 | 1.19 Million USD | -61.88% |
| 2020 Q3 | 3.05 Million USD | -2.52% |
| 2020 Q4 | 3.29 Million USD | 7.8% |
| 2020 FY | 3.29 Million USD | -55.01% |
| 2020 Q1 | 7.29 Million USD | -0.22% |
| 2020 Q2 | 3.13 Million USD | -57.09% |
| 2019 Q4 | 7.31 Million USD | -15.43% |
| 2019 FY | 7.31 Million USD | -15.67% |
| 2019 Q2 | 7.26 Million USD | -39.68% |
| 2019 Q3 | 8.64 Million USD | 19.09% |
| 2019 Q1 | 12.03 Million USD | 38.8% |
| 2018 Q3 | 8.73 Million USD | 32.51% |
| 2018 FY | 8.67 Million USD | 57.54% |
| 2018 Q4 | 8.67 Million USD | -0.69% |
| 2018 Q2 | 6.58 Million USD | 8.73% |
| 2018 Q1 | 6.06 Million USD | 10.1% |
| 2017 Q1 | 3.91 Million USD | 16.0% |
| 2017 FY | 5.5 Million USD | 63.08% |
| 2017 Q4 | 5.5 Million USD | 17.51% |
| 2017 Q3 | 4.68 Million USD | -18.91% |
| 2017 Q2 | 5.77 Million USD | 47.54% |
| 2016 Q2 | 4.42 Million USD | 43.24% |
| 2016 Q4 | 3.37 Million USD | -31.75% |
| 2016 Q1 | 3.09 Million USD | 27.09% |
| 2016 Q3 | 4.94 Million USD | 11.65% |
| 2016 FY | 3.37 Million USD | 38.72% |
| 2015 Q1 | 3.82 Million USD | -13.86% |
| 2015 Q2 | 3.1 Million USD | -18.82% |
| 2015 Q3 | 3.32 Million USD | 7.25% |
| 2015 FY | 2.43 Million USD | -45.15% |
| 2015 Q4 | 2.43 Million USD | -26.87% |
| 2014 FY | 4.43 Million USD | 72.67% |
| 2014 Q1 | 3.01 Million USD | 17.44% |
| 2014 Q3 | 4.27 Million USD | 2.2% |
| 2014 Q4 | 4.43 Million USD | 3.81% |
| 2014 Q2 | 4.18 Million USD | 38.58% |
| 2013 Q3 | 10.72 Million USD | 7.28% |
| 2013 Q4 | 2.56 Million USD | -76.05% |
| 2013 Q1 | 10.27 Million USD | -20.92% |
| 2013 Q2 | 9.99 Million USD | -2.72% |
| 2013 FY | 2.56 Million USD | -80.24% |
| 2012 Q2 | 7.57 Million USD | 14.79% |
| 2012 Q3 | 11.96 Million USD | 57.97% |
| 2012 FY | 12.99 Million USD | 134.3% |
| 2012 Q4 | 12.99 Million USD | 8.63% |
| 2012 Q1 | 6.59 Million USD | 18.94% |
| 2011 Q1 | 5.73 Million USD | 0.0% |
| 2011 FY | 5.54 Million USD | -3.23% |
| 2011 Q3 | 4.96 Million USD | 26.2% |
| 2011 Q2 | 3.93 Million USD | -31.41% |
| 2011 Q4 | 5.54 Million USD | 11.81% |
| 2010 Q1 | 2.48 Million USD | -4.86% |
| 2010 Q2 | 1.9 Million USD | -23.63% |
| 2010 Q4 | 5.73 Million USD | 131.73% |
| 2010 FY | 5.73 Million USD | 119.24% |
| 2010 Q3 | 2.47 Million USD | 30.21% |
| 2009 FY | 2.61 Million USD | 56.87% |
| 2009 Q1 | 2.44 Million USD | 46.79% |
| 2009 Q2 | 2.53 Million USD | 3.6% |
| 2009 Q3 | 1.38 Million USD | -45.36% |
| 2009 Q4 | 2.61 Million USD | 88.81% |
| 2008 Q2 | 1.93 Million USD | -12.24% |
| 2008 FY | 1.66 Million USD | -23.78% |
| 2008 Q3 | 2.16 Million USD | 11.73% |
| 2008 Q4 | 1.66 Million USD | -22.9% |
| 2008 Q1 | 2.2 Million USD | 0.82% |
| 2007 FY | 2.18 Million USD | -67.26% |
| 2007 Q4 | 2.18 Million USD | -17.87% |
| 2007 Q3 | 2.66 Million USD | -6.76% |
| 2007 Q1 | 6.91 Million USD | 3.46% |
| 2007 Q2 | 2.85 Million USD | -58.67% |
| 2006 FY | 6.68 Million USD | 38.16% |
| 2006 Q1 | 5.88 Million USD | 21.61% |
| 2006 Q4 | 6.68 Million USD | -7.43% |
| 2006 Q2 | 6.77 Million USD | 15.17% |
| 2006 Q3 | 7.21 Million USD | 6.56% |
| 2005 Q2 | 5.67 Million USD | 7.08% |
| 2005 FY | 4.83 Million USD | -5.03% |
| 2005 Q1 | 5.29 Million USD | 4.09% |
| 2005 Q4 | 4.83 Million USD | -15.71% |
| 2005 Q3 | 5.73 Million USD | 1.09% |
| 2004 Q1 | 7.76 Million USD | 86.79% |
| 2004 Q4 | 5.09 Million USD | 10.77% |
| 2004 Q3 | 4.59 Million USD | -5.95% |
| 2004 Q2 | 4.88 Million USD | -37.05% |
| 2004 FY | 5.09 Million USD | 22.5% |
| 2003 Q4 | 4.15 Million USD | -10.28% |
| 2003 Q3 | 4.63 Million USD | 171.83% |
| 2003 FY | 4.15 Million USD | 183.88% |
| 2003 Q1 | 4.12 Million USD | 181.83% |
| 2003 Q2 | 1.7 Million USD | -58.7% |
| 2002 Q2 | 818 Thousand USD | -39.41% |
| 2002 Q3 | 934 Thousand USD | 14.18% |
| 2002 Q4 | 1.46 Million USD | 56.75% |
| 2002 FY | 1.46 Million USD | 15.09% |
| 2002 Q1 | 1.35 Million USD | 6.13% |
| 2001 Q3 | 1.24 Million USD | 11.32% |
| 2001 Q1 | 1.23 Million USD | -17.12% |
| 2001 Q2 | 1.12 Million USD | -9.44% |
| 2001 Q4 | 1.27 Million USD | 1.84% |
| 2001 FY | 1.27 Million USD | -14.92% |
| 2000 Q4 | 1.49 Million USD | 65.49% |
| 2000 Q2 | 1.24 Million USD | 5.39% |
| 2000 Q3 | 903.38 Thousand USD | -27.44% |
| 2000 FY | 1.49 Million USD | -0.33% |
| 2000 Q1 | 1.18 Million USD | -21.24% |
| 1999 Q2 | 2.2 Million USD | 29.41% |
| 1999 Q3 | 2.1 Million USD | -4.55% |
| 1999 Q4 | 1.5 Million USD | -28.57% |
| 1999 FY | 1.5 Million USD | 36.36% |
| 1999 Q1 | 1.7 Million USD | 54.55% |
| 1998 Q4 | 1.1 Million USD | 22.22% |
| 1998 Q2 | 1 Million USD | 25.0% |
| 1998 Q1 | 800 Thousand USD | 0.0% |
| 1998 Q3 | 900 Thousand USD | -10.0% |
| 1998 FY | 1.1 Million USD | 37.5% |
| 1997 Q2 | 900 Thousand USD | -10.0% |
| 1997 Q1 | 1 Million USD | -9.09% |
| 1997 Q3 | 1.4 Million USD | 55.56% |
| 1997 Q4 | 800 Thousand USD | -42.86% |
| 1997 FY | 800 Thousand USD | -27.27% |
| 1996 FY | 1.1 Million USD | -86.75% |
| 1996 Q2 | 1.6 Million USD | 14.29% |
| 1996 Q1 | 1.4 Million USD | -83.13% |
| 1996 Q4 | 1.1 Million USD | 0.0% |
| 1996 Q3 | 1.1 Million USD | -31.25% |
| 1995 Q4 | 8.3 Million USD | 0.0% |
| 1995 FY | 8.3 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -284.975% |
| Armata Pharmaceuticals, Inc. | 142.02 Million USD | 93.56% |
| Actinium Pharmaceuticals, Inc. | 45.06 Million USD | 79.703% |
| Azitra, Inc. | 2.2 Million USD | -315.331% |
| Can-Fite BioPharma Ltd. | 3.74 Million USD | -144.18% |
| Chromocell Therapeutics Corporation | 6.54 Million USD | -39.842% |
| Calidi Biotherapeutics, Inc. | 18.25 Million USD | 49.89% |
| CEL-SCI Corporation | 17.31 Million USD | 47.168% |
| iBio, Inc. | 7.41 Million USD | -23.441% |
| Lineage Cell Therapeutics, Inc. | 38.99 Million USD | 76.544% |
| MAIA Biotechnology, Inc. | 7.08 Million USD | -29.025% |
| Matinas BioPharma Holdings, Inc. | 46.33 Million USD | 80.258% |
| Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | 26.911% |
| NovaBay Pharmaceuticals, Inc. | 5.72 Million USD | -59.913% |
| NanoViricides, Inc. | 1.35 Million USD | -573.179% |
| Oragenics, Inc. | 1.79 Million USD | -408.681% |
| BiomX Inc. | 55.07 Million USD | 83.392% |
| BiomX Inc. | 55.07 Million USD | 83.392% |
| Protalix BioTherapeutics, Inc. | 50.86 Million USD | 82.017% |
| Palatin Technologies, Inc. | 10.85 Million USD | 15.725% |
| Scorpius Holdings, Inc. | 22.74 Million USD | 59.782% |